If you join this study, you will have a 50/50 chance of getting either the study drug (DMX-200) or a placebo. A placebo looks like the real medicine but has no active ingredients. This “double-blind” setup means neither you nor the study doctor will know which one you are getting, unless there is an emergency. The study has several parts. First is the Screening and Qualification period to see if you can join. This may include changing your ARB dose (up to 4 weeks) and keeping it the same for 6 weeks. You will use an electronic diary (or paper diary if needed) to track your medicines, symptoms, and other study details. If you qualify, you will move to the Treatment period where you take the study medicine twice a day on an empty stomach, give blood and urine samples, and answer questions about your health and quality of life. After that, there is a Follow-up period to check your health after you stop the study medicine. You may also be asked to join an optional 2-year extension, where everyone gets the study drug. In total, the study may last up to 122 weeks (about 28 months) unless you choose to leave early. All visits, medicines, tests, and procedures will be free. You will get $150 for each in-person visit to help with travel and meal costs.

Who can Participate

You may join the study if you are between 18 and 80 years old and have primary FSGS or FSGS with an unknown cause. Your diagnosis must have been confirmed by a kidney biopsy or proven to be genetic, and it must have been made within the past 7 years. You must already be taking an ARB medicine or be willing to start one. You also need to have a protein-to-creatinine ratio (PCR) greater than 1.5 g/g and an estimated glomerular filtration rate (eGFR) between 25 and 120 mL/min/1.73 m².

Study ID